Table 2 Characteristics and preoperative data of patients undergoing major hepatectomy
Characteristics | Chemotherapy | No chemotherapy (n = 30) | p value | |
|---|---|---|---|---|
SP index ≥ 1.2 (n = 12) | SP index < 1.2 (n = 14) | |||
Gender (male/female) | 8/4 | 8/6 | 14/16 | 0.48 |
Age | 58.3 ± 12.4 | 63.6 ± 10.3 | 63.0 ± 10.0 | 0.38 |
BMI | 22.9 ± 3.1 | 21.3 ± 2.7 | 22.8 ± 3.8 | 0.23 |
Diabetes mellitus (+) | 4 | 3 | 5 | 0.49 |
Hepatitis virus (+) | 0 | 0 | 2 | 0.41 |
Number of chemotherapy cycles (median, range) | 12 (5–27) | 8 (1–23) | – | 0.21 |
SP index | 1.65 ± 0.60 | 1.04 ± 0.05 | – | < 0.001 |
Splenic volume before chemotherapy | 131.7 ± 48.2 | 112.4 ± 49.4 | – | 0.23 |
Splenic volume before hepatectomy | 214.3 ± 88.8 | 117.7 ± 56.9 | 160.9 ± 162.0 | 0.004 |
Laboratory tests before hepatectomy | ||||
 Platelet count (× 109/L) | 171 ± 60 | 231 ± 97 | 234 ± 72 | 0.029 |
 AST (IU/L) | 33.3 ± 11.7 | 24.8 ± 7.8 | 26.7 ± 9.3 | 0.035 |
 ALT (IU/L) | 30.5 ± 18.9 | 19.2 ± 13.6 | 22.2 ± 13.5 | 0.032 |
 ALP (IU/L) | 371.6 ± 161.3 | 410.9 ± 186.3 | 303.8 ± 159.2 | 0.050 |
 Albumin (g/dL) | 3.9 ± 0.3 | 3.9 ± 0.4 | 4.1 ± 0.2 | 0.014 |
T-Bil (mg/dL) | 0.9 ± 0.4 | 0.9 ± 0.4 | 0.9 ± 0.3 | 0.94 |
 PT-INR | 1.02 ± 0.08 | 1.04 ± 0.09 | 1.08 ± 0.10 | 0.17 |
 ICG-R15 (%) | 12.3 ± 5.9 | 10.2 ± 6.0 | 7.9 ± 3.9 | 0.061 |
Future remnant liver volume (%) | 55.9 ± 12.8 | 49.3 ± 18.5 | 53.5 ± 13.8 | 0.42 |
TSH/PVE | 3 | 4 | 2 | 0.12 |